ArticleP & T : a peer-reviewed journal for formulary management2017

Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Timothy C Hutcherson et al.PubMed ↗Full text ↗

No numbers read from the abstract.